Saturday, 31 October 2026European Markets

AUREA Stock Was Up By 11.51% Before The Weekend

Loading stream...

(vianews) - the market ended the session with aurea (aure.pa) jumping 11.51% to €5.62 on friday while cac 40 slid 1.51% to €7,500.26.

aurea's last close was €5.04, 22.7% under its 52-week high of €6.52.

about aurea

aurea sa engages in the recycling of black motor oil in france. the company is also involved in the manufacturing of remold tires from used tires and recycling rigid pvc. it recycles plastics and packaging products; refines and recycles aluminum; recycles copper and produces copper alloys; and treats and recycles zinc, lead, and cadmium. in addition, the comany engages in the treatment and decontamination of mercury waste. the company was formerly known as auer and changed its name to aurea sa in 1988. aurea sa is based in paris, france.

earnings per share

as for profitability, aurea has a trailing twelve months eps of €0.49.

pe ratio

aurea has a trailing twelve months price to earnings ratio of 11.47. meaning, the purchaser of the share is investing €11.47 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.57%.

yearly top and bottom value

aurea's stock is valued at €5.62 at 22:30 est, way under its 52-week high of €6.52 and way above its 52-week low of €4.30.

moving average

aurea's worth is under its 50-day moving average of €5.65 and above its 200-day moving average of €5.22.

more news about aurea (aure.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com